Loss of PIM2 enhances the anti-proliferative effect of the pan-PIM kinase inhibitor AZD1208 in non-Hodgkin lymphomas

BACKGROUND: A promising therapeutic approach for aggressive B-cell Non-Hodgkin lymphoma (NHL), including diffuse large B-cell lymphoma (DLBCL), and Burkitt lymphoma (BL) is to target kinases involved in signal transduction and gene regulation. PIM1/2 serine/threonine kinases are highly expressed in...

Descripción completa

Detalles Bibliográficos
Autores principales: Kreuz, S., Holmes, K. B., Tooze, R. M., Lefevre, P. F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4672512/
https://www.ncbi.nlm.nih.gov/pubmed/26643319
http://dx.doi.org/10.1186/s12943-015-0477-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4672512/
https://www.ncbi.nlm.nih.gov/pubmed/26643319
http://dx.doi.org/10.1186/s12943-015-0477-z

Ejemplares similares